Skip to main content

Day: May 21, 2025

Request for delisting of Svitzer’s shares from Nasdaq Copenhagen A/S

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION IN WHICH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL Reference is made to Svitzer Group A/S’ (Svitzer) company announcement dated 16 May 2025 regarding the final result and completion of APMH Invest A/S’ (APMHI) all-cash voluntary recommended purchase offer to acquire all of the issued shares (the Shares) in Svitzer, except for Shares owned by APMHI and Shares held by Svitzer and/or its subsidiaries in treasury, if any. Following a request from APMHI, Svitzer’s Board of Directors has today decided to request Nasdaq Copenhagen A/S (Nasdaq Copenhagen) to have Svitzer’s Shares (ISIN DK0062616637) removed from trading and official listing at Nasdaq Copenhagen. Provided that Nasdaq Copenhagen accepts the request, the delisting will be completed with...

Continue reading

Final results for the financial year ended 31 March 2025

       Delivering a milestone year for ICG    HighlightsAUM of $112bn; fee-earning AUM of $75bn, up 8%1 compared to FY24 and five-year annualised growth of 14%1 $24bn of fundraising, securing cycle and underpinning near-term financial performance Management fees of £604m, up 19%2 compared to FY24 Performance fee income of £86m (FY24: £74m) Total Balance Sheet Return of £241m3 Fund Management Company profit before tax of £461m, up 23% compared to FY24 Group profit before tax of £532m; NAV per share of 859p Operating cashflow of £518m, up 44% compared to FY24 (£359m) Total ordinary dividend per share for FY25 of 83p, 15th consecutive annual increase Reiterating medium-term guidance Will seek shareholder approval at 2025 Annual General Meeting to change name to “ICG plc”Note: unless otherwise stated the financial results...

Continue reading

TCM Group A/S: Interim report Q1 2025

COMPANY ANNOUNCEMENT No. 207/2025         Tvis, 21 May 2025 Interim report Q1 2025 (January 1 – March 31) (All figures in brackets refer to the corresponding period in 2024) Organic sales growth driven by a recovering B2C market. CEO Torben Paulin:“Sales in the first quarter developed in line with our expectations, with a decline in B2B project sales offset by a robust increase in B2C sales. Total sales for the quarter rose by 5% year-on-year to DKK 308 million, with an organic growth of 4%. Order intake showed positive development in the first quarter, with growth in both the B2C and B2B segments, and across all our brands. Additionally, we observed early signs of recovery in the Norwegian market, marked by double-digit growth in order intake. The gross margin increased to 21.1% in Q1, compared to 20.5% in Q1 2024, primarily due...

Continue reading

Wix Reports First Quarter 2025 Results

Strong start to year with Q1’25 total bookings of $511 million, up 12% y/y, with very robust top of funnel demand in the quarter and new cohort strength continuing through April and early May Q1’25 total revenue of $474 million exceeded expectations, up 13% y/y, driven by accelerating Self Creators growth accompanied by solid Partners momentum as Studio adoption continued to ramp healthily Launched Wixel, a new standalone AI-powered visual design platform that brings the most advanced creative tools into a single intuitive interface and puts complete visual editing control into the hands of everyone – marking Wix’s milestone foray into creation beyond websites Achieved FCF margin of 30% in Q1’25 as we continued to maintain a resilient operating cost structure amidst robust top-line performance Increased share repurchase board authorization...

Continue reading

CMB.TECH announces Q1 2025 results

CMB.TECH ANNOUNCES Q1 2025 RESULTS 1 BILLION USD CONTRACT BACKLOG ADDED ANTWERP, Belgium, 21 May 2025 – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the Company”) (NYSE: CMBT & Euronext: CMBT) reported its non-audited financial results today for the first quarter ended 31 March 2025. HIGHLIGHTS Financial highlights:Profit of USD 40.4 million in Q1 2025 CMB.TECH increases its contract backlog by USD 921 million (to USD 2.94 billion)Corporate highlights:CMB.TECH buys Hemen stake in Golden Ocean Term sheet signed for a stock-for-stock merger transaction between CMB.TECH and Golden OceanFleet highlights:Fortescue and CMB.TECH sign agreement for ammonia-powered Newcastlemax CMB.TECH and MOL sign landmark agreement for nine ammonia-powered vessels Delivery of 5 newbuilding vessels: Mineral Portugal, Mineral Osterreich, Mineral Suomi,...

Continue reading

Prosafe SE: First-quarter results 2025

(Figures in brackets refer to the corresponding period last year) 21 May 2025 – Prosafe SE reported EBITDA of USD 4.6 million (USD 7.2 million) for the first quarter of 2025. The company had four active vessels during the quarter. Operations and HSSEGood operating performance Safe Zephyrus extended with Petrobras to Q3 2027 Sale of Safe Concordia and Safe Scandinavia Safe Caledonia re-activated for UK contract with start 1 June Safe Boreas in transit to Singapore ahead of Australia contract Safe Notos declared winner of Brazil 4-year tenderQ1 financialsRevenues of USD 33 million (USD 34 million) and EBITDA of USD 4.6 million (USD 7.2 million) Cash flow from operations of USD 28.4 million (negative USD 1.4 million) including contract prepayments for Safe Boreas and Safe Caledonia Capex of USD 21.2 million (USD 1.7 million) due...

Continue reading

Orion’s collaborator, MSD, expands clinical development program for opevesostat to women’s cancers

ORION CORPORATION INVESTOR NEWS 21 MAY 2025 at 07.30 EEST                    Orion’s collaborator, MSD, expands clinical development program for opevesostat to women’s cancers Orion’s collaborator, MSD, has expanded the development program for opevestostat (MK-5684) to now include women’s cancers. A new Phase 2 clinical trial evaluating the safety and efficacy of opevesostat for the treatment of breast, endometrial and ovarian cancers has been posted to ClinicalTrials.gov database. The study is not yet recruiting patients. Further information is available on ClinicalTrials.gov:A Study of MK-5684 in People With Certain Solid Tumors (study identifier: NCT06979596)MSD has global exclusive rights to opevesostat which is an oral, non-steroidal and selective inhibitor of CYP11A1 discovered and developed by Orion. MSD is currently evaluating...

Continue reading

CoinShares Expands XBT Provider Platform with Seven New Physical Crypto ETPs

May 21, 2025 | SAINT HELIER, Jersey | CoinShares International Limited (“CoinShares” or “the Group”) (Nasdaq Stockholm: CS; US OTCQX: CNSRF), a leading global investment company specializing in digital assets with over $6 billion in AUM, announces the expansion of its Swedish XBT Provider Platform with the launch of seven new physically-backed crypto Exchange Traded Products (ETPs). CoinShares is leveraging its well-established and respected Swedish platform, CoinShares XBT Provider AB, to offer investors access to new digital assets with best-in-class structuration, cost-effective management fees, and staking rewards for proof-of-stake cryptocurrencies. Each product employs physical replication, meaning the underlying cryptocurrencies purchased and directly held in a regulated custodian. The seven new products,...

Continue reading

Cipher Mining Prices Convertible Senior Notes Offering and Hedging Transaction to Place Borrowed Common Stock

NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) — Cipher Mining Inc. (NASDAQ: CIFR) (“Cipher” or the “Company”) today announced the pricing of its public offering of $150,000,000 aggregate principal amount of convertible senior notes due 2030 (the “notes”) in an offering registered under the Securities Act of 1933, as amended. The issuance and sale of the notes are scheduled to settle on May 22, 2025, subject to customary closing conditions. Cipher also granted the underwriters of the notes offering a 30-day option to purchase up to an additional $22,500,000 aggregate principal amount of notes solely to cover over-allotments. Morgan Stanley is acting as sole bookrunning manager for the offering. Keefe, Bruyette & Woods, A Stifel Company is acting as co-manager for the offering. The notes will be senior, unsecured obligations of Cipher,...

Continue reading

ASUS and AMD Jointly Unveil Full 2025 Expert P Series Lineup at AMD Keynote

A full portfolio of AI PCs tailor-made for SMBsTORONTO, May 20, 2025 (GLOBE NEWSWIRE) —  ASUS and AMD today jointly announced the launch of the all-new ASUS Expert P-series Copilot+ PCs at Computex 2025, spotlighting its leadership in the commercial AI PC space. Powered by the latest AMD Ryzen™ AI 300 Series processors, the new lineup includes ExpertBook P3 (PM3) laptop, ExpertCenter P700 (PM700MK, PM700SK) desktops, ExpertCenter P600 (PM640, PM670) all-in-one PCs, and ExpertCenter PN54 Mini PC. These next-generation business devices are engineered to deliver lightning-fast AI computing, seamless productivity, and enhanced security for working professionals — all within a future-ready, sustainable design. “We’re proud to deepen our collaboration with AMD as we usher in a new era of AI-powered computing. At ASUS, we believe...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.